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Natural and man-made chemicals in the
environment can exert hormone mimetic or
antagonist activity. Bisphenol A (BPA), a
widely used chemical with mixed estrogen
agonist/antagonist properties, is employed in
the manufacture of plastics used in dental
prostheses and sealants (Suzuki et al. 2000), in
the linings of metal cans used to preserve
foods (Kang et al. 2003), and in such items as
baby bottles (Brede et al. 2003) and the clear
plastic cages used in many research institu-
tions to house laboratory animals (Howdeshell
et al. 2003). The low afﬁnity of BPA for the
cell nuclear estrogen receptors ER-α and
ER-β and weak bioactivity in standard tests of
estrogenicity, such as the rat uterotrophic
assay (Ashby 2001), have led to the conclu-
sion that human BPA exposure is probably
insufficient to elicit significant estrogenic
responses [Degen et al. 2002; European
Commission (EC) Scientific Committee on
Food 2002; U.S. Environmental Protection
Agency (EPA) 1993]. Whether the endocrine
activity of BPA is accurately reﬂected in such
tests, however, remains controversial, because
of the potential for tissue and cell-specific
estrogen effects (Safe et al. 2002). Of particu-
lar concern, several reports have indicated
that BPA exposure inhibits sexual differentia-
tion of nonreproductive behaviors, including
maze learning behavior (Carr et al. 2003;
Farabollini et al. 2002), at doses as much as
1,000-fold lower than those required for
stimulation of uterine growth (Ashby 2001).
The mechanisms underlying these low-dose
effects remain unknown.
Sexual differentiation of the brain is
believed to involve neurotrophic effects of
estrogens, mediated at least in part via activa-
tion of kinase-dependent signaling cascades
(Toran-Allerand et al. 1999). Kinase-associated
neuroplastic responses to estrogen are also
expressed in adulthood, in the cornu ammonis
(CA) pyramidal neurons of the hippocampus
(Bi et al. 2001; McEwen 2002). In adult
female rats (Woolley and McEwen 1992) as
well as nonhuman primates (Leranth et al.
2002), estradiol induces a rapid increase in
CA1 pyramidal cell dendritic spine synapse
density (PSSD), a response that has been pos-
tulated to involve intermediate activation of
the mitogen-activated protein (MAP) kinase
cascade (Bi et al. 2001). We reasoned that if
BPA inhibits sexual differentiation of the
rodent brain, there might also be significant
interactions between estradiol and BPA with
respect to the regulation of hippocampal CA1
PSSD. Consistent with this hypothesis, in rat
hippocampal organotypic cultures, regulation
of NMDA receptors, which are critical compo-
nents of the mechanisms responsible for estro-
gen regulation of CA1 dendritic spine density
(Woolley and McEwen 1994), has been
reported to be sensitive to nanomolar concen-
trations of either 17β-estradiol (E2) or BPA
(Sato et al. 2002). Therefore, in the present
study, we examined the effects of estradiol and
BPA, alone and in combination, on CA1
PSSD in adult ovariectomized (OVX) rats.
Our results indicate that BPA does indeed
have potent effects on the regulation of CA1
PSSD. However, the data demonstrate that,
rather than inducing estrogen-like responses,
BPA antagonizes the rapid inductive effects of
estrogen on hippocampal PSSD.
Materials and Methods
Animals.  Experimental protocols were
approved by the Institutional Animal Care and
Use Committee of Yale University, where all
studies using animals were performed. Adult
female Sprague-Dawley rats (250–300 g;
Charles River Laboratories, Wilmington, MA,
USA) were used. The rats were ovariectomized
under ketamine/xylazine/acepromazine anes-
thesia (3 mL/kg intramuscular injection of a
cocktail containing 25 mg ketamine, 1.2 mg
xylazine, and 0.03 mg acepromazine in 1 mL
saline).
Morphologic studies. One week after
ovariectomy, animals were treated with estro-
gen, using groups of three animals per treat-
ment condition. In the first PSSD study,
15 rats (ﬁve groups of three rats) were injected
subcutaneously with either 17β-E2 (60 µg/kg;
12 rats) or the sesame oil vehicle (200 µL;
three rats). Nine of the 12 estradiol-treated
animals were treated simultaneously with
increasing doses (40, 120, and 400 µg/kg) of
BPA (> 99% purity; Sigma-Aldrich, St. Louis,
MO, USA). In the second PSSD experiment,
12 rats were injected subcutaneously (three
rats per treatment) with 17α-E2 (45 µg/kg),
BPA (300 µg/kg), a combination of 17α-E2
(45 µg/kg) plus BPA (300 µg/kg), or the
sesame oil vehicle (200 µL) alone. Thirty min-
utes after injection, animals were sacrificed
under deep ether anesthesia by transcardial
perfusion of heparinized saline followed by a
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Bisphenol A (BPA) is an estrogenic chemical that is widely used in the manufacture of plastics and
epoxy resins. Because BPA leaches out of plastic food and drink containers, as well as the BPA-
containing plastics used in dental prostheses and sealants, considerable potential exists for human
exposure to this compound. In this article we show that treatment of ovariectomized rats with BPA
dose-dependently inhibits the estrogen-induced formation of dendritic spine synapses on pyramidal
neurons in the CA1 area of the hippocampus. Signiﬁcant inhibitory effects of BPA were observed at
a dose of only 40 µg/kg, below the current U.S. Environmental Protection Agency reference daily
limit for human exposure. Because synaptic remodeling has been postulated to contribute to the
rapid effects of estrogen on hippocampus-dependent memory, these data suggest that environ-
mental BPA exposure may interfere with the development and expression of normal sex differences
in cognitive function, via inhibition of estrogen-dependent hippocampal synapse formation. It may
also exacerbate the impairment of hippocampal function observed during normal aging, as endoge-
nous estrogen production declines. Key words: bisphenol A, CA1, estradiol, hippocampus, spine
synapse density. Environ Health Perspect 113:675–679 (2005). doi:10.1289/ehp.7633 available via
http://dx.doi.org/ [Online 24 February 2005]
The Environmental Estrogen Bisphenol A Inhibits Estradiol-Inducedﬁxative containing 4% paraformaldehyde and
0.1% glutaraldehyde in 0.1 M phosphate
buffer (pH 7.35). The brains were removed
and postfixed overnight in the same fixative
without glutaraldehyde. The hippocampi
were then dissected out, and 100 µm vibra-
tome sections were cut perpendicular to the
longitudinal axis of the hippocampus. The
approximately 90 vibratome sections were
divided into 10 subgroups using systematic
random sampling and were ﬂat-embedded in
Araldite (Electron Microscopy Sciences, Fort
Washington, PA, USA).
To correct for processing-induced changes
in the volume of the tissue, we calculated a
correction factor assuming that the treatments
did not alter the total number of pyramidal
cells. In all hippocampi, we examined six or
seven disector pairs (pairs of adjacent 2-µm
semi-thin sections mounted on slides and
stained with toluidine blue). We calculated a
pyramidal cell density value (D) using the for-
mula D = N/sT, where N is the mean disector
score across all sampling windows, T is the
thickness of the sections (2 µm), and s is the
length of the window. Based on these values, a
dimensionless volume correction factor kv was
introduced: kv = D/D1, where D1 is the mean
cell density across the groups of hippocampi
(Rusakov et al. 1997).
To exclude the possibility that alterations
in PSSD might be a consequence of changes
in the volume of reference, we used a subset
of the vibratome sections for volume estima-
tion of the stratum radiatum of CA1, using
the Cavalieri’s principle (Gundersen and
Jensen 1987). Areas of CA1 stratum radiatum
were measured in each section using Scion
Image software (Scion Corp., Frederick, MD,
USA), and the total volume of CA1 stratum
radiatum in each rat was estimated as
where T is the distance between the top of
one sampled section and the top of the next
section, and A(CA1SR)n is the measured area
of CA1 stratum radiatum for each section.
Thereafter, serial ultrathin sections were
cut from randomly sampled vibratome sec-
tions and collected on formvar-coated single-
slot grids. Disector pairs of digitized electron
micrographs (“reference” and “look-up”) were
taken from adjacent ultrasections at a magni-
ﬁcation of 11,000× in a Tecnai 12 transmis-
sion electron microscope (FEI Company,
Hillsboro, OR, USA) furnished with an AMT
Advantage 4.00 HR/HR-B CCD camera sys-
tem (Hamamatsu Photonics, Hamamatsu,
Japan), from an area located between the upper
and middle third of the CA1 stratum radiatum
(300–500 µm from the pyramidal cell layer;
Leranth et al. 2004). Identical regions in adja-
cent sections were identiﬁed using landmarks
such as myelinated fibers, large dendrites, or
blood vessels that did not change signiﬁcantly
between neighboring sections. The investiga-
tor taking the electron micrographs was
blinded to the treatment of individual ani-
mals. Areas occupied by potentially interfering
structures such as blood vessels, large den-
drites, or glial cells were subtracted from the
measured ﬁelds. The digitized electron micro-
graphs were printed out using a laser printer
and coded. The code was not broken until the
analysis was completed. Synapses were counted
using a two-dimensional unbiased counting
frame with an area of 79 µm2 superimposed on
the electron microscopic prints. Only those
spine synapses were counted that were present
in the reference micrograph but not in the
look-up micrograph, and vice versa. At least
10 disector pairs were photographed on each
electron microscopic grid. With at least three
grids (containing two adjacent ultrathin sec-
tions) prepared from each vibratome section
(cut from three different regions of the hippo-
campus along its longitudinal septotemporal
axis), each animal provided at least 3 × 3 ×
10 × 2 = 180 neuropil fields for evaluation.
The density of spine synapses in each animal
was calculated as 
where ΣQ(syn) is the total number of synapses
sampled by the disector; 2 × 90 = 180 is the
number of evaluated electron micrographs per
animal; the section thickness t was measured
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Figure 1. BPA inhibits the effect of 17β-E2 on CA1 PSSD. (A) At 30 min after 17β-E2 injection, PSSD
increased by almost 100%. (B) The PSSD response to 17β-E2 is inhibited in a dose-dependent manner by
coadministration of BPA. Data in all cases represent mean ± SD of independent observations from three
rats at each dose level. In the case of the 120-µg/kg dose, the bars indicating SD are so close to the mean
that they are partially obscured by the symbol. The line through the points represents the four-parameter
logistic best-ﬁt regression analysis of the data. The ED50 for BPA inhibition of the 17β-estradiol–induced
increase in PSSD, calculated from the four-parameter curve ﬁt, is 117 µg/kg. 
*Signiﬁcantly different from oil-injected controls (p < 0.001, Student t-test). **Signiﬁcantly different from PSSD in animals
treated with 17β-E2 alone (Bonferroni-Dunn post hoc test, p < 0.05).
Figure 2. High-power electron micrographs taken from the CA1 stratum radiatum of rats treated with either
(A) 60 µg/kg 17β-E2 or (B) 60 µg/kg 17β-E2 + 400 µg/kg BPA. Arrows indicate spine synapses. Bar = 500 nm.by the method of Small’s smallest fold (Weibel
1979; average 0.075 µm); and 79 is the area of
the counting frame in square micrometers.
PSSD for each animal was calculated by divid-
ing Nv(syn) by the volume correction factor kv.
Rat uterine weight assay. To assess utero-
trophic responses, a separate group of 12 rats
(four groups of 3) was treated 1 week after
ovariectomy with subcutaneous injections of
17β-E2 (60 µg/kg), BPA (400 µg/kg), or the
combination of BPA (400 µg/kg) and 17β-E2
(60 µg/kg), daily for 3 days. Control animals
received the sesame oil vehicle (200 µL/day)
alone. Six hours after the last injection, the
animals were sacrificed; their uteri were dis-
sected free of adhering fat and connective tissue,
drained of intraluminal ﬂuid, and weighed.
Statistical analysis. Results, in all cases, are
presented as mean ± SD of observations from
three animals per treatment group. We have
veriﬁed that the use of three animals per treat-
ment group provides sufﬁcient statistical power
to detect effects of the magnitude typically
observed after steroid replacement, because of
the precision obtained by analyzing large num-
bers of sections per animal. SDs for counting
CA1 synapses in this laboratory are usually
< 5% of mean PSSD. With an SD of 5% and
sample sizes of three per group, a 15% change
in mean PSSD can be detected with α = 0.05
and 80% power. In the present studies, SDs
for measurement of PSSD were in most
instances considerably < 5% of mean.
Data were analyzed statistically using
Statview (SAS Institute, Cary, NC, USA) or
SPSS for Windows (Systat Inc., Chicago, IL,
USA). We used Bartlett’s test to verify homo-
geneity of variance. One- and two-way analysis
of variance (ANOVA) and the Bonferroni-
Dunn test were used for comparison of 
individual treatment groups. When only con-
trol versus treatment comparisons were con-
sidered, we used the Student t-test. Four-
parameter least-squares regression analysis of
the BPA dose–response data was performed
using ALLFIT (DeLean et al. 1978).
Results
Treatment of OVX rats with 17β-E2 (60 µg/kg
body weight) increased CA1 PSSD almost
2-fold (Figure 1A). This dose of 17β-E2 has
previously been shown to induce a maximal
PSSD response (MacLusky et al. 2005).
Treatment with BPA did not further enhance
hippocampal synapse formation but dose-
dependently inhibited the effect of 17β-E2
(Figures 1B, 2). At a BPA dose of 400 µg/kg,
the PSSD response to 17β-E2 was completely
inhibited, compared with the CA1 PSSD in
OVX vehicle-treated animals. Four-parameter
least-squares regression analysis (DeLean et al.
1978) determined a median effective dose
(ED50) of 117 µg/kg for BPA inhibition of the
response to 17β-E2.
Increased uterine weight is a widely
accepted bioassay for estrogen action (Ashby
2001). Therefore, we determined whether the
dose of BPA (400 µg/kg) found to block induc-
tion of PSSD produced comparable inhibition
of uterotrophic responses. Administration of
the highest dose of BPA daily for 3 days only
marginally inhibited the uterotrophic effect of
17β-E2 (Figure 3). These results are consistent
with previous reports that BPA exerts weak
antagonist effects on some uterine responses to
estradiol at doses < 100 mg/kg, although it acts
as an estrogen agonist at higher dose levels
(Ashby 2001).
Like several other responses of neurons to
estrogen (Green et al. 1997; Levin-Allerhand
et al. 2002; Yu et al. 2004), PSSD is sensitive to
both the 17α and 17β isomers of estradiol, the
17α isomer being considerably more potent as
an inducer of CA1 spine synapses (MacLusky
et al. 2005), despite the fact that it has very low
uterotrophic activity (Lundeen et al. 1997).
We therefore determined whether BPA also
interferes with the synaptic effects of 17α-E2.
Treatment with 17α-E2 at 45 µg/kg induced
an increase in PSSD similar to that elicited by
60 µg/kg 17β-E2 (Figure 4; compare with
Figure 1). Administration of 300 µg/kg BPA
alone significantly reduced PSSD. The same
dose of BPA also inhibited the increase in
PSSD induced by 17α-E2 (Figure 4). The
mean PSSD observed after treatment with the
combination of BPA and 17α-E2 was not sig-
niﬁcantly different from that observed in OVX
vehicle-injected controls.
In neither of the two PSSD studies was
there any signiﬁcant variation in the total vol-
ume of the CA1 stratum radiatum (Table 1),
conﬁrming the validity of the volume correc-
tion procedure used in calculating PSSD.
Discussion
Our data indicate that low-dose BPA exposure
inhibits the rapid hippocampal synaptogenic
response to estradiol. The minimum BPA
dose required to elicit this effect is within the
range of dose levels believed, until now, to
have little or no significant biologic impact,
even under conditions of long-term BPA
exposure. In the United States, the current
U.S. Environmental Protection Agency (EPA)
maximum acceptable “reference” dose for
chronic BPA ingestion is 50 µg/kg /day, calcu-
lated as 0.1% of the lowest observed adverse
effect level (LOAEL) determined from toxicity
studies (U.S. EPA 1993). The corresponding
Article | Bisphenol A inhibits hippocampal synaptogenesis
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Figure 3. BPA administration only slightly impairs
the uterotrophic response to 17β-E2. Two-way
ANOVA: 17β-E2 effect, F = 301.2, df 1,8, p < 0.0001;
BPA effect, F = 11.1, df 1,8, p = 0.01; 17β-E2 × BPA
interaction, F = 0.29, df 1,8, p > 0.6.
Figure 4. BPA inhibits the effects of 17α-E2 on CA1
PSSD. In the absence of BPA, 17α-E2 induced an
increase in synapse density of 0.463 synapses/µm3,
a 65% increase above the mean synapse density in
vehicle-injected controls. In the presence of BPA,
the effect of the estrogen was reduced to an
increase of 0.192 synapses/µm3, 39% above the
level observed in animals treated with BPA alone.
Two-way ANOVA: 17α-E2 effect, F = 237.3, df 1,8,
p < 0.0001; BPA effect, F = 292.8, df 1,8, p < 0.0001;
17α-E2 × BPA interaction, F = 40.8, df 1,8, p = 0.0002. 
*Significantly higher PSSD than in vehicle-treated rats,
without BPA (Student t-test, p < 0.05). **Significant
inhibitory effect of BPA compared with animals given the
same vehicle or 17α-E2 without BPA (Bonferroni-Dunn
post hoc test, p < 0.05).
Table 1. Effect of 17β-E2 or 17α-E2 with or without
BPA on total CA1 stratum radiatum volume (mean
± SD).
CA1 stratum
radiatum 
Treatment volume (mm3)
17β-E2
Vehicle control 3.84 ± 0.15
60 µg/kg 17β-E2 3.99 ± 0.26
60 µg/kg 17β-E2 + 40 µg/kg BPA 3.96 ± 0.16
60 µg/kg 17β-E2 + 120 µg/kg BPA  4.05 ± 0.49
60 µg/kg 17β-E2 + 400 µg/kg BPA 3.93 ± 0.43
17α-E2
Vehicle control 3.97 ± 0.42
45 µg/kg 17α-E2 3.97 ± 0.39
300 µg/kg BPA 3.97 ± 0.37
45 µg/kg 17α-E2 + 300 µg/kg BPA 3.77 ± 0.19
The volume of CA1 stratum radiatum was measured in the
animals used for spine synapse counting (n = 3 animals
per group). For animals treated with 17β-E2 ± BPA,
synapse densities are shown in Figure 1; one-way ANOVA:
F = 0.162, df 4,10, p > 0.95. For animals treated with 17α-E2
± BPA, synapse densities are shown in Figure 4; one-way
ANOVA: F = 0.241, df 3,8, p > 0.85.European Commission tolerable daily intake
(TDI; 10 µg/kg/day) is based on the assump-
tion of a 500-fold safety margin over the no
observed effect level (NOEL) dose derived from
three-generation rat reproductive toxicity trials
(EC Scientiﬁc Committee on Food 2002). In
OVX rats, our data indicate that a single BPA
dose of 40 µg/kg, below the U.S. EPA refer-
ence dose and only 4-fold higher than the
European Commission TDI safe daily limit, is
sufficient to significantly impair the PSSD
response to maximal 17β-E2 stimulation.
Under conditions of low physiologic estrogen
exposure, as is the case during prepubertal
development as well as after reproductive
senescence, considerably lower doses of BPA
may be sufﬁcient to interfere with the synap-
togenic effects of the hormone. Circumstantial
evidence supporting the view that the effects
of BPA are not confined to rapid PSSD
responses to estrogen administration is pro-
vided by the data for OVX rats. Even with-
out estrogen treatment, in OVX rats BPA
significantly reduced CA1 PSSD (Figure 4).
Preliminary data from our laboratories indi-
cate that the “baseline” PSSD observed in
OVX rats includes a contribution from the
phytoestrogens present in normal rat chow.
Removal of these estrogens, by feeding with
phytoestrogen-free chow, reduces CA1 PSSD
to levels comparable with those observed in
the present study after treatment of OVX ani-
mals with BPA (Leranth C, Hajszan T,
MacLusky NJ, unpublished data).
Estradiol has important neurotrophic and
neuroprotective functions in the brain, in
addition to its role as a reproductive steroid
(Nathan et al. 2004). A growing body of evi-
dence indicates that estradiol is synthesized in
the hippocampus (Hojo et al. 2004), provid-
ing a local source of estrogen onto which the
effects of circulating levels of the hormone are
superimposed. Because synapse formation in
the hippocampus is believed to be involved in
the mechanisms mediating the acquisition and
retention of memory (Silva 2003), interference
with estrogen action in the hippocampus
could have serious long-term consequences.
Deficiencies in gonadal steroid-induced
stimulation of hippocampal synaptogenesis
have been suggested to contribute to neuro-
degenerative disorders and age-related cogni-
tive impairment, for which women with low
bioavailable circulating estradiol concentra-
tions appear to be at enhanced risk (Gandy
2003; Yaffe et al. 2000). The ability of BPA to
block the effects of estrogen on CA1 PSSD
raises the possibility that chronic environ-
mental exposure to BPA might interfere with
estrogen effects on the development and func-
tion of the brain, inhibiting normal sex differ-
ences in nonreproductive behavior (Carr et al.
2003; Farabollini et al. 2002) as well as exacer-
bating the negative impact on the aging brain
of declining gonadal hormone levels (Gandy
2003; Yaffe et al. 2000). Although it remains
to be determined whether such effects have a
signiﬁcant impact on the health of human and
animal populations exposed to BPA, the cur-
rent exposure limits clearly do not provide a
wide margin of safety in terms of the acute
estrogen-dependent regulation of CA1 PSSD.
The mechanisms responsible for BPA’s
effects remain unknown. BPA interacts with a
number of hormone receptor systems, includ-
ing androgen and thyroid receptors as well as
ER-α and ER-β (Moriyama et al. 2002;
Wetherill et al. 2002; Zoeller et al. 2005), pro-
viding several potential pathways through
which BPA could interfere with hippocampal
synaptogenesis. Recent work has demonstrated
that BPA and 17β-E2 are equipotent activators
of CREB phosphorylation in pancreatic islet
cells, a response mediated via a “nonclassical”
membrane ER (Quesada et al. 2002).
Although the in vitro equilibrium binding
afﬁnities of ER-α and ER-β for BPA are low
(Kuiper et al. 1998a), this does not preclude
the possibility that BPA could act via these ERs
as well because rapid membrane ER-mediated
responses may not reﬂect equilibrium binding
afﬁnity. ER-α and ER-β both partially localize
to the plasma membrane, where they mediate
activation of kinase-dependent signaling path-
ways. Induction of these rapid kinase-mediated
mechanisms exhibits a different pharmacologic
speciﬁcity than do nuclear receptor–activated
responses. Thus, activation of extracellular-
signal–regulated kinase (ERK) phosphorylation
in rat-2 cells transfected with ER-α or ER-β is
equally sensitive to 17α-E2 and 17β-E2 (Wade
et al. 2001), despite the large difference that
exists between these steroids in nuclear ER-α
and ER-β equilibrium binding afﬁnity (Kuiper
et al. 1998b) and uterotrophic activity
(Lundeen et al. 1997). Studies in bone cells and
ER-transfected HeLa cells suggest that rapid
membrane receptor–activated responses to
estrogen have a much broader ligand speciﬁcity
than do slower nuclear receptor–mediated tran-
scriptional effects because ER ligand association
rates tend to have a much more relaxed struc-
tural specificity than do dissociation rates.
Therefore, ligands that are incapable of forming
stable nuclear ER complexes because they disso-
ciate rapidly from the receptor may, nonethe-
less, modulate membrane ER-mediated effects
(Kousteni et al. 2001).
Circumstantial evidence points to a role for
nonclassical receptor mechanisms in the hip-
pocampal response to estrogen. Effects of
17β-E2 on CA1 dendritic structure are accom-
panied by increased ERK phosphorylation (Bi
et al. 2001), as well as changes in the distribu-
tion of the phosphorylated form of the serine-
threonine kinase Akt in CA1 pyramidal cell
dendrites (Znamensky et al. 2003). The fact
that 17α-E2 and 17β-E2 both induce an
increase in PSSD is consistent with the
hypothesis that membrane-associated ERs may
mediate rapid estrogen activation of CA1 spine
synapse formation (Wade et al. 2001). That
the rapid actions of estradiol on CA1 PSSD
involve nonclassical ER systems is also sug-
gested by recent data from this laboratory
demonstrating that short-term induction of
CA1 spine synapses requires relatively high cir-
culating 17β-E2 concentrations (MacLusky
et al. 2005). The effects of BPA on rapid estro-
gen induction of CA1 PSSD may reﬂect inter-
ference, directly or indirectly, with this putative
novel estrogen response pathway. Such a
hypothesis would be consistent with recent
studies in Mytilus that have demonstrated
marked inhibition of p38 MAP kinase phos-
phorylation by low concentrations of BPA, a
response diametrically opposite to that of estra-
diol (Canesi et al. 2004, 2005). A critical
experiment for future studies will be to deter-
mine whether the effects on hippocampal
PSSD of sustained physiologic circulating lev-
els of 17β-E2 (Woolley and McEwen 1992),
which may involve a greater contribution from
nuclear ER-α and/or ER-β, are similarly
affected by low-dose BPA exposure.
In summary, these data demonstrate that
the environmental estrogen BPA inhibits
estrogen-activated hippocampal spine synapse
formation. Because hippocampal spine
synapses are believed to be involved in the
mechanisms responsible for the formation of
memory (Silva 2003), these observations raise
concerns regarding the potential impact of
low-dose continuous BPA exposure on cogni-
tive development and function. In addition,
they further emphasize the dangers inherent
in reliance on only one or a few nuclear ER-
dependent tests as a basis for environmental
estrogen risk assessment (Safe et al. 2002).
There may be other compounds in the
environment—natural and man-made—that,
like 17α-E2 and BPA, exert potent effects on
neural estrogen response mechanisms, even
though their reported afﬁnities for ER-α and
ER-β are low. If so, current screening methods
for the evaluation of putative estrogen-like
“endocrine disruptors” (U.S. EPA 1998) may
underestimate the potential risk of exposure to
such compounds.
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